Interventional Oncology Service Line

Interventional Oncology (IO) is a rapidly developing field among physicians trained as Interventional Radiologists. These physicians are trained to be the experts in image-guided and minimally invasive procedures. They use the most advanced diagnostic equipment, molecular imaging, and non-invasive therapies to directly target, treat and manage many difficult-to-treat cancers and related disorders. Using a multidisciplinary approach, they work with other specialists including medical oncology, surgical oncology and radiation oncology to provide comprehensive cancer care.

Some of the minimally invasive therapies utilized by Interventional radiologists in IO include chemoembolization, radioembolization, radiofrequency ablation (RFA), selective internal radiation therapy (SIRT), cryoablation and more. Many of these procedures are done on an outpatient or overnight basis. In many situations, this can be an alternative to or supplement surgical treatment for many conditions and can result in shorter recovery times, fewer side effects and decreased hospitalizations. There are also many other new and developing technologies that have the potential to manage cancer in a more focused, effective, economical, and less invasive manner.

The goal of the RFS IO Service line is to provide high-quality resources and information regarding the 1) clinical, 2) practice building, 3) technical and 4) imaging components of oncologic diseases that can be treated through minimally invasive procedures performed by interventional radiologists. The IO Service line is currently subdivided into subcommittees based on the four components mentioned above.

Current Members

Chair:
Jeffrey Farrell

Vice Chairs:
Shanchita Ghosh – Survival Guide / Procedural Education
Jeffrey Sung – Wikipedia Enrichment
Omar Zuberi – Practice Building / Referral Education
Justin Shafa – Journal Primers

Active Members:
Alex Sheu
Dave Sarver
Erica Alexander
Jeffrey Farrell
Derek Khorsand
Rana Hunaid
Michael Hsu
Mina Makary
Myles Nightingale
Justin Shafa
Omar Szube
Jordan Fenlon
Jeffrey Sung
Shanchita Ghosh
Yosef Frenkel
Omar Zuberi
Nicholas Cleveland
Elena Violari
Daryl Goldman
Sukjin Koh
Jacob Grant
Andrew Perez
Marco Ertreo

Faculty Advisor:
Robert Lewandowski

Recommended Reading

Journal Primers

Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using deb chemoembolization

Comparison of Combination Therapies in the Management of Hepatocellular Carcinoma: Transarterial Chemoembolization with Radiofrequency Ablation versus Microwave Ablation

A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma

Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma

Multicenter Randomized Controlled Trial of Percutaneous Cryoablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma

Open-­Label Single-­Arm Phase II Trial of Sorafenib Therapy with Drug-­eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results

Development of Hong Kong Liver Cancer Staging System with Treatment Stratification for patient with HCC

A Single-­‐Incision Technique for Placement of Implantable Venous Access Ports via the Axillary Vein

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma results of the PRECISION V study

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

Sorafenib in advanced hepatocellular carcinoma

Survival Guides

Other Resources

National Meetings:

 
Disclaimer: Appearance of a conference on this list alone does not imply endorsement by SIR. This is a list of conferences compiled by SIR RFS members pertinent to Interventional Oncology. Please see each conference’s website for a list of affiliations and endorsements. Please contact the RFS IO service line chair with any comments or suggestions.

3,482 total views, 0 views today